Allan leads the Systems Genomics group at IMB and has had a leading role in the analysis of the genomic data generated from the SALSA-SGC collection. He has recently been funded to extend the ‘omits data with the inclusion of neurological protein measures in plasma.
Taking results from animal models, this project will screen blood lipids found to be markers of disease progression. Serum and plasma samples accessed from SALSA-SGC will be used for targeted screening of blood lipids knowing that lipid metabolism plays a crucial role in MND. This research will be conducted at the Florey Institute in Melbourne, Victoria, and results are expected late 2022.
Interested in finding out more about this study? Please contact Sophia Luikinga: firstname.lastname@example.org
Work has been undertaken with Illumina over the last 12 months to develop a SNP bead chip that will expand our capacity to screen for mutations associated with MND. The first batch of chips were received early 2022.
van Rheenen, W., van der Spek, R.A.A., Bakker, M.K. et al. Nat Genet 53, 1636–1648 (2021). https://doi.org/10.1038/s41588-021-00973-1
Restuadi, R., Garton, F.C., Benyamin, B. et al. Eur J Hum Genet 30, 532–539 (2022). https://doi.org/10.1038/s41431-021-00885-y
Nabais, M.F., Laws, S.M., Lin, T. et al. Genome Biol 22, 90 (2021). https://doi.org/10.1186/s13059-021-02275-5